Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary (VERITAS)
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary - VERITAS
Sponsor: AbbVie
A observational or N/A phase clinical study on Chronic Hepatitis C, this trial is completed. The trial is conducted by AbbVie and has accumulated 10 data snapshots since 2015. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Aug 2019 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Aug 2019 [monthly]
Completed
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Feb 2018 — Apr 2018 [monthly]
Active Not Recruiting NA
-
Aug 2017 — Feb 2018 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Aug 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
- IST GmbH, Germany
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.